Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBio-Sustainable Future Enterprises Regulatory News (BSFA)

Share Price Information for Bio-Sustainable Future Enterprises (BSFA)

Share Price is delayed by 15 minutes
Get Live Data
1.125    0.00 (0.00%)
Bid:
1.00
Ask:
1.25
Spread: 0.25 (25.00%)
Market Cap: £2.18m
BSFA Live PriceLast checked at - London Stock Exchange

Intraday Bio-Sustainable Future Enterprises Share Chart

3DBT Lab Grown Leather Commercialization

13 Mar 2025 07:00

RNS Number : 4353A
BSF Enterprise PLC
13 March 2025
 

 

 

 

 

London, 12 March 2025

 

BSF Enterprise PLC

 

3DBT Accelerates 

Lab-Grown Leather Commercialization

 

 

BSF Enterprise PLC (BSF), a leading innovator in tissue-engineered materials, is pleased to announce that its subsidiary, 3D Bio-Tissues Ltd (3DBT), has stepped up it's activities to commercialise the Lab-grown Leather business as part of the £50,000 Northern Accelerator Growth Support Grant.

 

BSF has previously formed a wholly owned subsidiary - Lab-grown Leather Ltd (LGL) and together with 3DBT they are taking steps aimed to transition the lab-grown leather technology from lab-scale to pilot plant and accelerate fundraising for its future commercialization.

 

LGL has entered collaborations with third parties to undertake market research to validate high-growth opportunities, evidence-defined revenue streams and align commercial efforts with key sectors such as fashion, jewellery, and automotive. It will also develop a comprehensive technology roadmap for a scalable production process and a clear plan for setting up a pilot plant.

 

This also involves developing a full business case for investment into LGL as a stand-alone entity in the lab-grown leather emerging industry. This investment will be non-dilutive to investors in BSF and will help position us to highlight the value of our advanced technology to new investors directly into LGL.

 

Further information will be released as we conclude the first stage of this development.

 

 

Dr. Che Connon, CEO and Founder of 3DBT, commented, "These collaborations have been developed over many months of discussions and will be critical in our launch of Lab-Grown Leather Ltd. It enables us to further accelerate the commercialization of our technology and scale up manufacturing."

 

3DBT and LGL remain committed to revolutionizing the leather industry through sustainable innovation and will provide further updates as the roadmap and pilot plant development progress.

 

 

For further enquiries, please visit www.bsfenterprise.com or contact:

 

BSF Enterprise PLC

Geoff Baker - Executive DirectorChe Connon - CEO & Director

 

Shard Capital (Broker)Damon HeathIsabella Pierre0207 186 90000207 186 9927

 

About BSF Enterprise PLC BSF Enterprise PLC (BSF) develops and commercialises cutting-edge tissue-engineered solutions, including lab-grown leather, cultivated meat, and corneal repair technologies. By leveraging its proprietary scaffold-free platform, BSF aims to deliver sustainable alternatives to traditional materials and meet global demand for environmentally responsible innovations.

 

About 3D Bio-Tissues 3D Bio-Tissues (3DBT) specialises in the creation of lab-grown tissues using advanced bioengineering techniques. Its scaffold-free lab-grown leather technology replicates the composition, texture, and performance of traditional leather without environmental and ethical drawbacks. For more information, visit www.3dbiotissues.com.

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCGPURCWUPAGQP
Date   Source Headline
16th Jun 20267:00 amRNSAuction Operational Update & Strategic Progress
12th Jun 20267:00 amRNSParis Auction Result
11th Jun 20267:00 amRNS£1 Million Convertible Loan Note
8th Jun 202611:59 amRNSShareholder meeting results
3rd Jun 20267:00 amRNSConditional Further Investment
2nd Jun 20268:50 amRNSTechnical White Paper on T-Rex Leather™
28th May 20267:00 amRNSAuction Update - May 2026
26th May 20267:00 amRNSStrategic Update May 2026
22nd May 20263:13 pmRNSPosting of Circular and Notice of General Meeting
5th May 20267:00 amRNST-Rex Leather™ handbag to be auctioned
17th Apr 202610:00 amRNSAdmission of Shares
13th Apr 20267:00 amRNSStrategic Shareholding Update
7th Apr 20267:00 amRNSWorld’s First T-Rex Leather Handbag Unveiled
2nd Apr 20267:00 amRNSWorld First T-Rex Leather™ Product
19th Mar 20267:00 amRNSSupply Agreement with SeaWith
17th Mar 20267:00 amRNSLGL Tanning Milestones
17th Mar 20267:00 amRNSLGL Tanning Milestones
13th Mar 20267:00 amRNSFurther Update on Fundraise & Reorganisation
13th Mar 20267:00 amRNSFurther Update on Fundraise & Reorganisation
10th Mar 202610:47 amRNSFirst Tannable A4-Sized Skin Achieved
10th Mar 202610:47 amRNSFirst Tannable A4-Sized Skin Achieved
3rd Mar 202611:00 amRNSResult of Annual General Meeting
27th Feb 20267:00 amRNSUpdate on Proposed Equity Fundraise
9th Feb 20267:00 amRNSNotice of 2026 AGM
3rd Feb 20265:14 pmRNSAnnual Financial Report - Correction
2nd Feb 20267:00 amRNSAnnual Financial Report
19th Jan 20267:00 amRNSKERATO LIMITED SIGNS WITH QUEBEC PSO GRANT
17th Dec 202511:08 amRNSResult of General Meeting
16th Dec 20257:00 amRNS3D Bio-Tissues Signs Supply Agreement with SeaWith
15th Dec 20257:00 amRNSChanges to timetable for proposed Equity Fundraise
5th Dec 20259:50 amRNS-RBSF Enterprise launches new Investor website
1st Dec 20257:02 amRNSProposed Equity Fundraise - Strategic Direction
1st Dec 20257:00 amRNSEquity Fundraise & Notice of General Meeting
29th Aug 202510:47 amRNSResignation of Chairman
10th Jul 20257:00 amRNSAgreement
25th Jun 20257:00 amRNSInterim 2025 Results
23rd May 20257:00 amRNS15p Warrants Amended
21st May 20257:00 amRNSLab-Grown Leather Ltd Progress
28th Apr 202510:01 amRNSStrategic Investment
25th Apr 20259:48 amRNSJoint Venture
13th Mar 20257:00 amRNS3DBT Lab Grown Leather Commercialization
6th Mar 20253:51 pmRNSPublication of a Prospectus
5th Mar 202512:10 pmRNSResult of Annual General Meeting
11th Feb 20258:21 amRNSExpected admission of shares - Replacement
11th Feb 20257:00 amRNSAIM Admission - Update
10th Feb 20257:00 amRNSAGM Statement
31st Jan 202512:41 pmRNSAnnual Financial Report
31st Jan 202512:31 pmRNSAnnual Financial Report
21st Jan 20257:00 amRNSBSF Enterprise and Sartorius
27th Dec 20247:00 amRNSAdmission of Placing Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.